利湿祛瘀法对Ⅲ型前列腺炎相关免疫学因素及PSA的影响
|
摘要
既往曾经认为慢性前列腺炎与前列腺癌无必定的内在联系,但近年来有关研究表明,慢性前列腺炎可能是前列腺癌的一个重要原因。已有研究提示免疫功能紊乱是前列腺癌发生发展的重要原因之一,同时也是前列腺炎和前列腺癌的共同特征。我院对前列腺癌的前期研究证实,通过调节免疫功能、扶正抑瘤的方法治疗晚期前列腺癌可以收到较好的疗效。同样,我院大量的实践与研究成果也表明,前列腺炎以湿热瘀阻的病机为主,以中医辨证为依据的利湿祛瘀法效果良好。前列腺炎好发于青壮年,且90%以上为非细菌性前列腺炎,免疫紊乱是一个重要因素,因此,我们设想,通过对前列腺炎患者有关瘤标及免疫相关指标的分析,中医药干预后的变化规律,以及建立前列腺炎患者的随访观察,或许能够对慢性前列腺炎与前列腺癌的内在联系,以及中医药对预防前列腺癌的作用得出有益的提示。
目的
观察Ⅲ型前列腺炎的免疫学变化,及其与前列腺特异抗原的关系,探讨中医利湿祛瘀对这些免疫指标的影响。以了解中医药辨证治疗对前列腺炎免疫学及其对前列腺特异抗原的影响,并作为对前列腺癌早期预防的初步探索。
方法
以广东省中医院泌尿外科门诊慢性Ⅲ型前列腺炎病人为样本52例,采用随机对照分组设置治疗组和对照组,分别通过治疗组根据辩证使用中医利湿祛瘀法(基本方加减治疗：川楝子10g元胡10g五灵脂10g蒲黄10g黄柏10g苍术10g牛膝10g苡米20g)；对照组则按照《中国泌尿外科疾病诊断治疗指南》推荐方案使用抗生素诺氟沙星治疗治疗,疗程2月。测定相关免疫指标,包括观察外周血T淋巴细胞亚群(CD3+T、CD4+T及CD8+T),血清PSA,前列腺按摩液EPS和TGF-β1的变化,对数据进行统计分析,对有关指标进行相关性分析,比较干预措施对免疫指标及PSA的影响。
结果
两组治疗前症状评分及生活质量评分之间均无统计学差别(P>0.05)。治疗2月后,治疗组各指标前后有显著差异(P<0.0001),对照组各指标前后数据除生活质量外都有统计学意义(P<0.05),生活质量前后无统计意义(P>0.05)。治疗后两组间均数有差别,其中两组间的疼痛症状、生活质量、整体总分差异具有显著意义(P<0.0001),而排尿症状两组间没有明显差异(P>0.05),症状总分两组间有统计学意义(P<0.05)。两组间各指标均差中排尿症状和生活质量有统计学意义(P<0.05)。两组间疼痛症状、症状评分、总体评分有显著性差异(P<0.0001)。
两组治疗前总前列腺特异抗原(TPSA)水平没有统计学差异,治疗一月对照组TPSA水平有所下降,与治疗前有统计差异(P<0.05),治疗组TPSA水平有所下降,但无统计意义,两组间无明显差别。治疗二月数据显示治疗组TPSA水平有所下降,与治疗前有统计差异(P<0.05),对照组TPSA水平有所下降,与治疗前相比有统计学意义(P<0.05),两组间无显著差别。两组FPSA/TPSA在治疗前后,及组间均无统计学意义(P>0.05)。
两组病例治疗前CD4+水平没有显著差异,治疗一月时治疗组CD4+水平有所上升,与治疗前无统计学意义(P>0.05),对照组CD4+水平有所上升,没有统计学意义(P>0.05)；两组间没有显著差别。治疗二月结果显示治疗组CD4+水平均有所上升,与治疗前有统计学意义(P<0.05),对照组CD4+水平有所上升,与治疗前相比无统计学意义(P<0.05)；两组间没有统计差别(P>0.05)。
两组病例治疗前CD8+水平没有统计差异,治疗一月时治疗组CD8+水平有所上升,与治疗前无统计学意义(P>0.05),对照组CD8+水平有所上升,没有统计学意义(P>0.05)；两组间没有统计差别。治疗二月结果显示治疗组CD8+水平均有所上升,与治疗前有统计学意义(P>0.05),对照组CD8+水平有所上升,与治疗前相比无统计学意义(P>0.05)；两组间没有统计差别(P>0.05)。
两组病例治疗前CD4+/CD8+水平没有显著差异,治疗一月时治疗组CD4+/CD8+水平有所上升,与治疗前无统计学意义(P>0.05),对照组CD4+/CD8+水平有所下降,没有统计学意义(P>0.05)；两组间没有统计差别。治疗二月结果显示治疗组CD4+/CD8+水平均有所上升,与治疗前没有统计学意义(P>0.05),对照组CD4+/CD8+水平有所上升,与治疗前相比无统计学意义(P<0.05)：两组间没有统计差别(P>0.05)。
两组病例治疗前CD3+水平没有显著差异,治疗一月时治疗组CD3+水平有所下降,与治疗前无统计学意义(P>0.05),对照组CD3+水平有所下降,没有统计学意义(P>0.05)；两组间没有显著差别。治疗二月结果显示治疗组CD3+水平有所上升,与治疗前无统计学意义(P>0.05),对照组CD3+水平有所下降,与治疗前相比无统计学意义(P>0.05)；两组间无统计差别(P>0.05)。
两组治疗前转化生长因子β1(TGF—β1)水平无显著差异,治疗一月时治疗组TGF-β1水平下降,与治疗前无统计意义(P>0.05),对照组TGF-β1水平有所下降,无统计学意义(P>0.05)；两组间没有显著差别。治疗二月结果显示治疗组TGF-β1水平有所下降,与治疗前有显著差异(P<0.0001),对照组TGF-β1水平下降,与治疗前相比有统计学意义(P<0.05)；两组间有统计学差异(P<0.05)。
结论
本研究在一定程度上证明Ⅲ型前列腺炎存在明显的免疫功能紊乱,表现在以整体的T淋巴亚群系列偏低表达为主,部分偏高表达的免疫功能紊乱,在这个层面上Ⅲ型前列腺炎与前列腺癌的免疫紊乱有一定的相似性,中医利湿祛瘀法为主的辨证治疗可以对这种免疫功能紊乱进行调节。该疗法对于细胞免疫的影响,首先明显地表现在对Th3细胞分泌的转化生长因子TGF-β1具有调节作用,其次这种中医疗法也可以在一定程度上改变CD4+CD8+CD3+以及CD4+/CD8+的低表达状态,提示该疗法可能有一定程度的抑制调节性T细胞的功能,同时描述性数据分析也显示出该疗法可能对细胞免疫具有调节作用。利湿祛瘀为主的中医疗法因此被认为具有调节Ⅲ型前列腺炎的免疫功能紊乱而使之趋于稳定平衡的作用。
另外在对于PSA的影响上,我们的结论是在2个月的疗程后这种中医疗法与诺氟沙星没有明显差异。研究证实利湿祛瘀法对Ⅲ型前列腺炎在改善症状、提高生活质量方面具有明显的临床疗效；表明湿热淤阻在前列腺炎的发病过程中起重要作用,研究从一个侧面揭示了前列腺炎的主要病机,这对于前列腺炎的深化研究具有重要意义。
Although the development of prostatic cancer is multi-factorial, accumulating evidences suggest that chronic prostatitis plays an important role in cancer development. Immune function disorder is considered as the common feature of prostatic cancer/carcinoma, as well as prosititis. My initial research confirmed that Traditional Chinese Medicine(TCM) is effective in treating advanced stage prostate cancer by regulating the immune function of patients and in curing prostatitis. So we assume that by analyzing the metastasis mark and immune-associated indexes of prostatic cancer patients, it is likely to get the curative regularity after TCM intervention, which may unveil the internal connections between chronic prostatitis and prostatic carcinoma, and may render a service to TCM preventive effect.
Object ive
To investigate the influence of dialectic TCM therapy on treating prostatitis, and to make preliminary research on prevention of prostatic carcinoma by observing the immunological changes of Category III prostatitis and their relationship with prostatic specific antigen (PSA), and by evaluating the effectiveness of damp elimination and stasis removing on these immunological indexes.
Materials and Methods
There were 52 cases of patients with Category III prostatitis which were from Urology Clinic of Guangdong Provincial Chinese medicine Hospital. The subjects were randomized to treatment group and control group. Patients in treatment group were treated with TCM therapy to eliminating dampness and removing blood stasis(Basic recipe plus or minus:Toosendan 10g Yuanhu 10g Wulingzhi 10g Puhuang 10g HuangbailOg Cangshu 10g Niuxi 15g Coix bidentata 20g). While subjects in control group were treated with antibiotics Norfloxacin. The course of treatment was two months. During the treatment course, a series of immune parameters/immunolization indicators were measured and observed, including peripheral blood T lymphocyte subsets (CD3 +T, CD4+ T and CD8+ T), serum PSA, prostatic EPS:TGF-β1. Statistical analysis of the data were made to compare the influence of interventions on immune parameters/immunolization indicators.
Results
Before treatment, the symptom score and quality of life score of two groups did not have statistical difference between (P>0.05). After 2 month treatment, in general, the most symptoms alleviated. Each index of the treatment group were significantly different compared with pre-treat level (P<0.0001). All the indicators of control group other than that of the quality of life have statistical significance (P<0.05). The quality of life had no statistically significant compared with pre-treat (P>0.05). After treatment, some differences between the average number of the two groups, of which the pain symptoms, quality of life, the overall total score difference was significant (P<0.0001), and the urinary symptoms between the two groups was no significant difference (P>0.05), total symptoms between the two groups was statistically significant (P<0.05). The average deviation between the two groups in urinary symptoms and quality of life have statistically significant (P<0.05), and the significant difference (P<0.0001) in the pain score, symptom score, overall score between two groups.
Before treatment, the level of total prostatic specific antigen (T-PSA) of two groups did not have significant difference. After 1 month treatment, the level of PSA of control group declined significantly compared with pre-treat level (P<0.05); but without significance; the T-PSA level of treatment group declined without significance; and there was no marked difference between the two groups. At the end of the second treatment course, T-PSA level of both groups declined with marked significance (p<0.05); and there is no significant difference between the two groups. No statistical meaning existed in F/T before and after treatment.
Before treatment, the CD4+/CD8+ level of two groups were not significantly different. At the end of the 1st month, CD4+/CD8+ level of the treatment group increased compared with pretherapy, with no significance (P>0.05); CD4+/CD8 +level of control group declined with no statistical significance (P>0.05); and there was no significant difference between the two groups. The 2nd month showed that the CD4+/CD8+ level of treatment group had risen, compared with pretherapy, which was significant (P<0.05). CD4+/CD8+ level of control group increased, compared with that pre-therapy condition but without significance (P>0.05); and no significant difference between the two groups (P>0.05).
Before treatment, CD3+ levels of two groups had no significant difference. In the 1st month, CD3+ level of the treatment group increased, but was not significant (P>0.05), the CD3+, level of the control group decreased, but was not statistically significant(P>0.05); there was no significant difference between the two groups. In the 2nd month, it showed that the CD3+ level of treatment group increased compared with pretherapy, and it was significant (P<0.05); CD3+ level of the control group decreased, compared with that pre-therapy, which was not significant (P<0.05); and there was significant difference between groups (P<0.05).
Before being treated, the transforming growth factorβ1 (TGF-β1) level of two groups was not significantly different. In the 1st month treatment, TGF-β1 level of the treatment group decreased, yet without significance (P> 0.05); that of control group declined was not statistically significant (P> 0.05); there was no significant difference between the two groups. In the 2nd month, it showed that the TGF-β1 level decreased in treatment group compared with pretherapy, without significance (P<0.05); the level of TGF-β1 of control group slightly increased compared with that pre-therapy conditions, which was not significant (P<0.05); and there was significant difference between the two groups (P<0.001).
Conclusions
The Research supported the point of view that obvious immune disorder exists in CategoryⅢprostatitis patients on some degree. Traditional Chinese medicine's eliminating dampness and removing stasis treatment can regulate the immune function disorder. In regard to the impact of PSA, after 2 months of treatment, there's no significant difference comparing Traditional Chinese Medicine therapy with the norfloxacin therapy. For the influence on cellular immunity, Traditional Chinese medicine can change, to some extent, the the low expression state of CD4+ CD8+ CD3+ and CD4+/CD8+, and regulate transforming growth factor TGF-β1 at the same time. Therefore, the TCM therapy on eliminating dampness and eliminating stasis was confirmed effective on regulating immune functional disorders of CategoryⅢprostatitis and on gearing immune function to normal level.
目的
观察Ⅲ型前列腺炎的免疫学变化,及其与前列腺特异抗原的关系,探讨中医利湿祛瘀对这些免疫指标的影响。以了解中医药辨证治疗对前列腺炎免疫学及其对前列腺特异抗原的影响,并作为对前列腺癌早期预防的初步探索。
方法
以广东省中医院泌尿外科门诊慢性Ⅲ型前列腺炎病人为样本52例,采用随机对照分组设置治疗组和对照组,分别通过治疗组根据辩证使用中医利湿祛瘀法(基本方加减治疗：川楝子10g元胡10g五灵脂10g蒲黄10g黄柏10g苍术10g牛膝10g苡米20g)；对照组则按照《中国泌尿外科疾病诊断治疗指南》推荐方案使用抗生素诺氟沙星治疗治疗,疗程2月。测定相关免疫指标,包括观察外周血T淋巴细胞亚群(CD3+T、CD4+T及CD8+T),血清PSA,前列腺按摩液EPS和TGF-β1的变化,对数据进行统计分析,对有关指标进行相关性分析,比较干预措施对免疫指标及PSA的影响。
结果
两组治疗前症状评分及生活质量评分之间均无统计学差别(P>0.05)。治疗2月后,治疗组各指标前后有显著差异(P<0.0001),对照组各指标前后数据除生活质量外都有统计学意义(P<0.05),生活质量前后无统计意义(P>0.05)。治疗后两组间均数有差别,其中两组间的疼痛症状、生活质量、整体总分差异具有显著意义(P<0.0001),而排尿症状两组间没有明显差异(P>0.05),症状总分两组间有统计学意义(P<0.05)。两组间各指标均差中排尿症状和生活质量有统计学意义(P<0.05)。两组间疼痛症状、症状评分、总体评分有显著性差异(P<0.0001)。
两组治疗前总前列腺特异抗原(TPSA)水平没有统计学差异,治疗一月对照组TPSA水平有所下降,与治疗前有统计差异(P<0.05),治疗组TPSA水平有所下降,但无统计意义,两组间无明显差别。治疗二月数据显示治疗组TPSA水平有所下降,与治疗前有统计差异(P<0.05),对照组TPSA水平有所下降,与治疗前相比有统计学意义(P<0.05),两组间无显著差别。两组FPSA/TPSA在治疗前后,及组间均无统计学意义(P>0.05)。
两组病例治疗前CD4+水平没有显著差异,治疗一月时治疗组CD4+水平有所上升,与治疗前无统计学意义(P>0.05),对照组CD4+水平有所上升,没有统计学意义(P>0.05)；两组间没有显著差别。治疗二月结果显示治疗组CD4+水平均有所上升,与治疗前有统计学意义(P<0.05),对照组CD4+水平有所上升,与治疗前相比无统计学意义(P<0.05)；两组间没有统计差别(P>0.05)。
两组病例治疗前CD8+水平没有统计差异,治疗一月时治疗组CD8+水平有所上升,与治疗前无统计学意义(P>0.05),对照组CD8+水平有所上升,没有统计学意义(P>0.05)；两组间没有统计差别。治疗二月结果显示治疗组CD8+水平均有所上升,与治疗前有统计学意义(P>0.05),对照组CD8+水平有所上升,与治疗前相比无统计学意义(P>0.05)；两组间没有统计差别(P>0.05)。
两组病例治疗前CD4+/CD8+水平没有显著差异,治疗一月时治疗组CD4+/CD8+水平有所上升,与治疗前无统计学意义(P>0.05),对照组CD4+/CD8+水平有所下降,没有统计学意义(P>0.05)；两组间没有统计差别。治疗二月结果显示治疗组CD4+/CD8+水平均有所上升,与治疗前没有统计学意义(P>0.05),对照组CD4+/CD8+水平有所上升,与治疗前相比无统计学意义(P<0.05)：两组间没有统计差别(P>0.05)。
两组病例治疗前CD3+水平没有显著差异,治疗一月时治疗组CD3+水平有所下降,与治疗前无统计学意义(P>0.05),对照组CD3+水平有所下降,没有统计学意义(P>0.05)；两组间没有显著差别。治疗二月结果显示治疗组CD3+水平有所上升,与治疗前无统计学意义(P>0.05),对照组CD3+水平有所下降,与治疗前相比无统计学意义(P>0.05)；两组间无统计差别(P>0.05)。
两组治疗前转化生长因子β1(TGF—β1)水平无显著差异,治疗一月时治疗组TGF-β1水平下降,与治疗前无统计意义(P>0.05),对照组TGF-β1水平有所下降,无统计学意义(P>0.05)；两组间没有显著差别。治疗二月结果显示治疗组TGF-β1水平有所下降,与治疗前有显著差异(P<0.0001),对照组TGF-β1水平下降,与治疗前相比有统计学意义(P<0.05)；两组间有统计学差异(P<0.05)。
结论
本研究在一定程度上证明Ⅲ型前列腺炎存在明显的免疫功能紊乱,表现在以整体的T淋巴亚群系列偏低表达为主,部分偏高表达的免疫功能紊乱,在这个层面上Ⅲ型前列腺炎与前列腺癌的免疫紊乱有一定的相似性,中医利湿祛瘀法为主的辨证治疗可以对这种免疫功能紊乱进行调节。该疗法对于细胞免疫的影响,首先明显地表现在对Th3细胞分泌的转化生长因子TGF-β1具有调节作用,其次这种中医疗法也可以在一定程度上改变CD4+CD8+CD3+以及CD4+/CD8+的低表达状态,提示该疗法可能有一定程度的抑制调节性T细胞的功能,同时描述性数据分析也显示出该疗法可能对细胞免疫具有调节作用。利湿祛瘀为主的中医疗法因此被认为具有调节Ⅲ型前列腺炎的免疫功能紊乱而使之趋于稳定平衡的作用。
另外在对于PSA的影响上,我们的结论是在2个月的疗程后这种中医疗法与诺氟沙星没有明显差异。研究证实利湿祛瘀法对Ⅲ型前列腺炎在改善症状、提高生活质量方面具有明显的临床疗效；表明湿热淤阻在前列腺炎的发病过程中起重要作用,研究从一个侧面揭示了前列腺炎的主要病机,这对于前列腺炎的深化研究具有重要意义。
Although the development of prostatic cancer is multi-factorial, accumulating evidences suggest that chronic prostatitis plays an important role in cancer development. Immune function disorder is considered as the common feature of prostatic cancer/carcinoma, as well as prosititis. My initial research confirmed that Traditional Chinese Medicine(TCM) is effective in treating advanced stage prostate cancer by regulating the immune function of patients and in curing prostatitis. So we assume that by analyzing the metastasis mark and immune-associated indexes of prostatic cancer patients, it is likely to get the curative regularity after TCM intervention, which may unveil the internal connections between chronic prostatitis and prostatic carcinoma, and may render a service to TCM preventive effect.
Object ive
To investigate the influence of dialectic TCM therapy on treating prostatitis, and to make preliminary research on prevention of prostatic carcinoma by observing the immunological changes of Category III prostatitis and their relationship with prostatic specific antigen (PSA), and by evaluating the effectiveness of damp elimination and stasis removing on these immunological indexes.
Materials and Methods
There were 52 cases of patients with Category III prostatitis which were from Urology Clinic of Guangdong Provincial Chinese medicine Hospital. The subjects were randomized to treatment group and control group. Patients in treatment group were treated with TCM therapy to eliminating dampness and removing blood stasis(Basic recipe plus or minus:Toosendan 10g Yuanhu 10g Wulingzhi 10g Puhuang 10g HuangbailOg Cangshu 10g Niuxi 15g Coix bidentata 20g). While subjects in control group were treated with antibiotics Norfloxacin. The course of treatment was two months. During the treatment course, a series of immune parameters/immunolization indicators were measured and observed, including peripheral blood T lymphocyte subsets (CD3 +T, CD4+ T and CD8+ T), serum PSA, prostatic EPS:TGF-β1. Statistical analysis of the data were made to compare the influence of interventions on immune parameters/immunolization indicators.
Results
Before treatment, the symptom score and quality of life score of two groups did not have statistical difference between (P>0.05). After 2 month treatment, in general, the most symptoms alleviated. Each index of the treatment group were significantly different compared with pre-treat level (P<0.0001). All the indicators of control group other than that of the quality of life have statistical significance (P<0.05). The quality of life had no statistically significant compared with pre-treat (P>0.05). After treatment, some differences between the average number of the two groups, of which the pain symptoms, quality of life, the overall total score difference was significant (P<0.0001), and the urinary symptoms between the two groups was no significant difference (P>0.05), total symptoms between the two groups was statistically significant (P<0.05). The average deviation between the two groups in urinary symptoms and quality of life have statistically significant (P<0.05), and the significant difference (P<0.0001) in the pain score, symptom score, overall score between two groups.
Before treatment, the level of total prostatic specific antigen (T-PSA) of two groups did not have significant difference. After 1 month treatment, the level of PSA of control group declined significantly compared with pre-treat level (P<0.05); but without significance; the T-PSA level of treatment group declined without significance; and there was no marked difference between the two groups. At the end of the second treatment course, T-PSA level of both groups declined with marked significance (p<0.05); and there is no significant difference between the two groups. No statistical meaning existed in F/T before and after treatment.
Before treatment, the CD4+/CD8+ level of two groups were not significantly different. At the end of the 1st month, CD4+/CD8+ level of the treatment group increased compared with pretherapy, with no significance (P>0.05); CD4+/CD8 +level of control group declined with no statistical significance (P>0.05); and there was no significant difference between the two groups. The 2nd month showed that the CD4+/CD8+ level of treatment group had risen, compared with pretherapy, which was significant (P<0.05). CD4+/CD8+ level of control group increased, compared with that pre-therapy condition but without significance (P>0.05); and no significant difference between the two groups (P>0.05).
Before treatment, CD3+ levels of two groups had no significant difference. In the 1st month, CD3+ level of the treatment group increased, but was not significant (P>0.05), the CD3+, level of the control group decreased, but was not statistically significant(P>0.05); there was no significant difference between the two groups. In the 2nd month, it showed that the CD3+ level of treatment group increased compared with pretherapy, and it was significant (P<0.05); CD3+ level of the control group decreased, compared with that pre-therapy, which was not significant (P<0.05); and there was significant difference between groups (P<0.05).
Before being treated, the transforming growth factorβ1 (TGF-β1) level of two groups was not significantly different. In the 1st month treatment, TGF-β1 level of the treatment group decreased, yet without significance (P> 0.05); that of control group declined was not statistically significant (P> 0.05); there was no significant difference between the two groups. In the 2nd month, it showed that the TGF-β1 level decreased in treatment group compared with pretherapy, without significance (P<0.05); the level of TGF-β1 of control group slightly increased compared with that pre-therapy conditions, which was not significant (P<0.05); and there was significant difference between the two groups (P<0.001).
Conclusions
The Research supported the point of view that obvious immune disorder exists in CategoryⅢprostatitis patients on some degree. Traditional Chinese medicine's eliminating dampness and removing stasis treatment can regulate the immune function disorder. In regard to the impact of PSA, after 2 months of treatment, there's no significant difference comparing Traditional Chinese Medicine therapy with the norfloxacin therapy. For the influence on cellular immunity, Traditional Chinese medicine can change, to some extent, the the low expression state of CD4+ CD8+ CD3+ and CD4+/CD8+, and regulate transforming growth factor TGF-β1 at the same time. Therefore, the TCM therapy on eliminating dampness and eliminating stasis was confirmed effective on regulating immune functional disorders of CategoryⅢprostatitis and on gearing immune function to normal level.
引文
[1]American Cancer Society. Cancer facts and figures,2006; May 13,2008.
[2]Penson DF, Chan JM:Prostate Cancer. In Urologic Diseases in America. Edited by m n Litwin MS, Saigal CS. Washington, DC:US Government Printing Office,2007; [NIH Publication No.07-5512:71-122.]
[3]DeMarzo AM, Platz EA, Sutcliffe S, et al.:Inflammation in prostate carcinogenesis. Nat Rev Cancer,2007; 7:256-269.
[4]McNaughton-Collins M, Joyce GF, Wise M, Pontari MA:Prostatitis. In Urologic Diseases in America. Edited by Litwin MS, Saigal CS. Washington, DC: US Government Printing Office,,2007; [NIH Publication No.07-5512:9-42.]
[5]Roberts R0, Lieber MM, Bostwick DG, Jacobsen SJ:A review of clinical and pathological prostatitis syndromes. Urology,1997; 49:809-821.
[6]Roberts R0, Lieber MM, Rhodes T, et al.:Prevalence of a physician-assigned diagnosis of prostatitis:the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology,1998; 51:578-584.
[7]Dennis LK, Lynch CF, Torner JC:Epidemiologic association between prostatitis and prostate cancer. Urology,2002; 60:78-83.
[8]Sarma AV, McLaughlin JC, Wallner, et al.:Sexual behavior, sexually transmitted diseases, and prostatitis:the risk of prostate cancer in black men. J Urol,2006; 176:1108-1113.
[9]Coussens LM, Werb Z:Inflammation and cancer. Nature 2002,420:860-867.
[10]Basler JW, Piazza GA:Nonsteroidal anti-inflamatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol,2004; 171:S59-S63.
[11]DeMarzo AM, Marchi VL, Epstein JI, Nelson WG:Proliferative inflammatory atrophy of the prostate. Implications for prostate carcinogenesis. Am J Pathol,1999; 155:1985-1992.
[12]Shah R, Mucci NR, Amin A, et al.:Postatrophic hyperplasia of the prostate gland. Neoplastic precursor or innocent bystander? Am J Pathol,2001; 158: 1767-1773.
[13]Anton RC, Kattan MW, Chakraborty S, Wheeler TM:Postatrophic hyperplasia of the prostate:lack of association with prostate cancer. Am J Surg Pathol, 1999; 23:939-936.
[14]Gerstenbluth RE, Seftel AD, MacLennan GT, et al.:Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol,2002; 167:2267-2270.
[15]Bill is A, Magna LA:Inflammatory atrophy of the prostate. Arch Pathol Lab Med,2003; 127:840-844.
[16]MacLennan GT, Eisenberg R, Fleshman RL, et al.:The influence of chronic inflammation in prostatic carcinogenesis:a 5-year followup study. J Urol, 2006; 176:1012-1016.
[17]Konig JE, Senge T, Allhoff EP, Konig W:Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate,2004; 58:121-129.
[18]Zheng SL, Liu W, Wiklund F, et al.:A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. Prostate,2006; 66:1556-1564.
[19]Yoshimura R, Sano H, Masuda C, et al.:Expression of Cox-2 in prostate carcinoma. Cancer,2000; 89:589-596.
[20]National Institutes of Health Summary Statement. National Institute of Health/National Institute of Diabetes and Digestive and Kidney Diseases workshop on chronic prostatitis. Bethesda, MD:December 1995.
[21]Nickel JC, Nyberg LM, Hennenfent M:Research guidelines for chronic prostatitis:consensus report from the fi rst National Institutes of Health International Prostatitis Collaborative Network. Urology,1999; 54:229-233.
[22]True LD, Berger RE, Rothman I, et al.:Prostate histopathology and chronic prostatitis/chronic pelvic pain syndrome:a prospective biopsy study. J Urol, 1999; 162:2014-2018.
[23]Carver BS, Bozeman CB, William Bj, Venable DD:The prevalence of men with National Institutes of Health category IV prostatitis and association with serum prostate specific antigen. J Urol,2003; 169:589-591.
[24]Okada K, Kojima M, Naya Y, et al.:Correlation of histological inflammation in needle biopsy specimens with serum prostate-specific antigen levels in men with negative biopsy for prostate cancer. Urology,2000; 55:892-898.
[25]Stancik I, Luftenegger W, Klimpfinger M, et al.:Effect of NIH-IV prostatitis on free and free-to-total PSA. Eur Urol,2004; 46:760-764.
[26]Rowe WEJ, Laniado ME, Walker MM, Anup P:Incidental acute prostatic inflammation is associated with a lower percentage of free prostate-specific antigen than other benign conditions of the prostate:a prospective screening study. BJU Int,2006; 97:1039-1042.
[27]Bozeman CB, Carver BS, Eastham JA, Venable DD:Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol,2002; 167:1723-1726.
[28]Nadler RB, Collins MM, Propert KJ, et al.:Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/chronic pelvic pain syndrome. Urology,2006; 67:337-342.
[29]Potts JM:Prospective identification of National Institutes of Health category Ⅳ prostatitis in men with elevated prostate specific antigen. J Urol 2000; 164:1550-1553.
[30]MILLAN-RODRIGUEZ F, PALOU J, BUJONS-TUR A, et al. Acute bacterial prostatitis:two different sub-categories according to a previous manipulation of the lower urinary tract[J]. World J Urol,2006,24(1):45-50
[31]TERAI A, ISHITOYA S, MITSUMORI K, et al. Molecular epidemiological evidence for ascending urethral infection in acute bacterial prostatitis [J]. J Urol,2000; 164(6):1945-1947
[32]张杰秀,华立新,钱立新,等.急性前列腺炎综合治疗35例报告[J].中华泌尿外科杂志,2005；26(12)：855
[33]王景顺,田浩,朱建周.感染性前列腺炎五年来菌谱及耐药性分析[J].医学信息,2006；19(2)：299-301
[34]ANDREU A, STAPLETON AE, FENNELL C, et al. Urovirulence determinants in Escherichia coli strains causing prostatit is[J]. J Infect Dis,1997, 176(2):464-469
[35]曹伟,代洪,童明华,等.慢性前列腺炎细菌感染及耐药性监测[J].中华医院感染学杂志,2003；13(8)：791-793
[36]胡小朋,白文俊,朱积川,等.慢性前列腺炎细菌及免疫学研究[J].中华泌尿外科杂志,2002；23(1)：29-31
[37]程力明,马文辉,赖秋亮,等.531例慢性前列腺炎病原体分析[J].中华男科学,2004；10(1)：64-65 185
[38]RIEGEL P, RUIMY R, DE BRIEL D, et al. Corynebacterium seminale sp. nov. a new species associated with genital infections in male patients[J]. J Clin Microbiol,1995; 33(9):2244-2249
[39]ROWE E, SMITH C, LAVERICK L, et al. A prospective, randomized, placebo controlled, double-blind study of pelvic electromagnetic therapy for the treatment of chronic pelvic pain syndrome with 1 year of followup[J]. J Urol, 2005; 173(6):2044-2047
[40]PONTARI MA, MCNAUGHTON-COLLINS M, O'LEARY MP, et al. The CPCRN Study Group. A case-control study of risk factors in men with chronic pelvic pain syndrome[J]. BJU Int,2005; 96(4):559-565
[41]孟安启,郑少斌,陈彤,等.慢性前列腺炎发病的多因素分析[J].第一军医大学学报,2002；22(9)：846-848
[42]SHORTLIFFE LM, SELLERS RG, SCHACHTER J. The characterization of nonbacterial prostatitis:search for an etiology[J]. J Urol,1992; 148(5):1461-1466
[43]PAVONE C, CALDARERA E, LIBERTI P, et al. Correlation between chronic prostatitis syndrome and pelvic venous disease:a survey of 2,554 urologic outpatients [J]. Eur Urol,2000; 37(4):400-403
[44]FORREST JB, SCHMIDT S. Interstitial cystitis, chronic nonbacterial prostatitis and chronic pelvic pain syndrome in men:a common and frequently identical clinical entity[J]. J Urol,2004; 172(6 Pt 2):2561-2562
[45]RILEY DE, BERGER RE, MINER DC, et al. Diverse and related 16S rRNA-encoding DNA sequences in prostate tissues of men with chronic prostatitis[J]. J Clin Microbiol,1998; 36(6):1646-1652
[46]ORHAN I, ONUR R, ILHAN N, et al. Seminal plasma cytokine levels in the diagnosis of chronic pelvic pain syndrome[J]. Int J Urol,2001; 8(9):495 499
[47]SZOKE I, TOROK L, D'OSA E, et al:The possible role of anaerobic bacteria in chronic prostatitis[J]. Int J Androl,1998,21 (3):163-168
[48]吕厚东,曹卉,李荣华,等.细菌L型与前列腺炎[J].男性学杂志,1994；8(3)：160 161.
[49]洪伟平,林观平,柯水源,等.性传播性尿道炎后慢性前列腺炎(附86例报告)[J].中华泌尿外科杂志,2002；23(5)：299-300
[50]OHKAWA M, YAMAGUCHI K, TOKUNAGA S, et al:Ureaplasma urealyticum in the urogenital tract of patients with chronic prostatitis or related symptomatology[J]. Br J Urol,1993; 186 72:918-921
[51]邓春华,梁宏,梅骅,等.前列腺内尿液反流在慢性前列腺炎发病中的作用[J].中华泌尿外科杂志,1998；19(6)：288-289
[52]PERSSON BE, RONQUISt G. Evidence for a mechanistic association between nonbacterial prostatitis and levels of urate and creatinine in expressed prostatic secretion[J]. J Urol,1996;155:958-960
[53]GHOBISH AA. Quantitative and qualitative assessment of flowmetrograms in patients with prostatodynia[J]. Eur Urol,2000; 38:576-583
[54]宋波,刘志平,金锡御,等.功能性膀胱下尿路梗阻与慢性前列腺炎[J].中华泌尿外科杂志,1995；16(2)：78
[55]MEHIK A, HELLSTROM P, LUKKARINEN 0, et al. Increased intraprostatic pressure in patients with chronic prostatitis[J]. Urol Res,1999; 27(4):277-279
[56]陈群,王翠华,严志强,等.慢性前列腺炎病人情绪因素与森田疗法[J],中华男科学,2003；9(9)：676—678
[57]陈修德,郑宝钟,金讯波,等.慢性前列腺炎的心理障碍及治疗[J],中华男科学,2004；10(2)：112-114
[58]TRIPP DA, CURTIS NICKEL J, LANDIS JR, et al. CPCRN Study Group. Predictors of quality of life and pain in chronic prostatitis/chronic pelvic pain syndrome: findings from the National Institutes of Health Chronic Prostatitis Cohort Study[J]. BJU Int,2004; 94(9):1279-1282
[59]HETRICK DC, CIOL MA, ROTHMAN I, et al. Musculoskeletal dysfunction in men with chronic pelvic pain syndrome type III:a case-control study[J]. J Urol,2003; 170(3):828-831
[60]周占松,宋波,卢根生,等.前列腺炎性疼痛与脊髓星形胶质细胞活化关系的研究[J].第三军医大学学报,2005；27(18)：1853-1854。
[61]陈勇,宋波,熊恩庆,等.前列腺与会阴盆底联系的电刺激研究[J].中华泌尿外科杂志,2004；25(2)：124-126
[62]SHAHED AR, SHOSKES DA. Correlation of beta-endorphin and prostaglandin E2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response[J]. J Urol,2001; 166 (5):1738-1741
[63]罗建辉,熊恩庆,宋波,等.非细菌性炎性刺激大鼠前列腺对膀胱功能影响的实验研究[J].第三军医大学学报,2005；27(21)：2145 2147 187
[64]周占松,宋波,卢根生,等.慢性前列腺炎牵涉痛神经机制及其膀胱、盆底肌的关系[J].解放军医学杂志,2005；30(12)：1055-1057
[65]周占松,宋波,卢根生,等.前列腺、膀胱及盆底肌伤害感受神经元在脊髓中的分布及其关系的研究[J].第三军医大学学报,2006；28(2)：157-159
[66]ALEXANDER RB, BRADY F, PONNIAH S. Autoimmune prostatitis:evidence of T cell reactivity with normal prostatic proteins [J]. Urology,1997; 50(6):893-899
[67]BATSTONE GR, DOBLE A, GASTON JS. Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS) [J]. Clin Exp Immunol,2002; 128(2):302-307
[68]JOHN H, BARGHORN A, FUNKE G, et al. Noninflammatory chronic pelvic pain syndrome:immunological study in blood, ejaculate and prostate tissue [J]. Eur Urol,2001; 39 (1):72-78
[69]DOBLE A, WALKER MM, HARRIS JR, et al. Intraprostatic antibody deposition in chronic abacterial prostatitis[J]. Br J Urol,1990,65(6):598-605
[70]范治璐,马悦,张萍,等.慢性非细菌性前列腺炎免疫学病因的探讨[J].中华泌尿外科杂志,2000；21(7)：446
[71]ALEXANDER RB, PONNIAH S, HASDAY J, et al. Elevated levels of proinflammatory cytokines in the semen of patients withchronic prostatitis/chronic pelvic pain syndrome[J]. Urology,52 (5):744-749
[72]NADLER RB, KOCH AE, CAMPBELL PL, et al. IL-1 beta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic pros tatitis [J]. J Urol,2000; 164(1):214-218
[73]SHAHED AR, SHOSKES DA. Oxidative stress in prostatic fluid of patients with chronic pelvic pain syndrome:correlation with gram positive bacterial growth and treatment response [J]. J Androl,2000; 21 (5):669-675
[74]PASQUALOTTO FF, SHARMA RK, POTTS JM, et al. Seminal oxidative stress in patients with chronic prostatitis[J]. Urology,2000; 55(6):881-5
[75]ORSILLES MA, DEPIANTE-DEPAOLI M. Oxidative stress-related parameters in prostate of rats with experimental autoimmune prostatitis[J]. Prostate,1998; 34(4):270-274
[76]VICARI E. Effectiveness and limits of antimicrobial treatment on seminal leukocyte concentration and related reactive oxygen species production in patients with male accessory gland infection[J]. Hum Reprod,2000; 15(12):2536-2544 188
[77]ZHOU JF, XIAO WQ, ZHENG YC, et al. Increased oxidative stress and oxidative damage associated with chronic bacterial prostatitis[J]. Asian J Androl,2006; 8(3):317-323
[78]NICKEL JC, ALEXANDER RB, SCHAEFFER AJ, et al. Chronic Prostatitis Collaborative Research Network Study Group. Leukocytes and bacteria in men with chronic prostatitis/chronic pelvic pain syndrome compared to asymptomatic controls[J]. J Urol,2003; 170(3):818-822
[79]Alexander RB, Ponniah S, Hasday J, et al. Elevated levels of proinflammatory cytoklnes In the semen of patients with chronic prostatitis. chronic pelvic pain syndrome[J]. Urology,1998; 52(5):744
[80]Rivero V, Carnaud C, Riera CM. Prostatein or stervid binding protein (PSBP) induces experimental autoimmune prostatitis(EAP) in NOD mice[J]. Clin Immunol,2002; 105(2):176
[81]Batstone GR, Doble A, Gaston JS. Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS)[J]. Clin Exp Immunol,2002; 128(2):302
[82]John H, Maake C, Barghorn A. Immunological alterations in the~aculate of chronic prostatitis patients:clues for autoimmunity[J]. Andrologia,2003; 35(5):294
[83]Diserio GP, Nowotny E. Experimental autoimmune protatitis:in vivo induction of the autoimmune response to lymphocytic soluble factors. Alterations at the endocrine metabolism level[J]. Am J Reprod Immunol,1998; 39(4):226
[84]Diserio GP, Nowotny E. Experimental autoimmune prostatitis: dihydrotestosterone influence over the immune response[J]. J Urol,2003; 170(6 Pt 1):2486
[85]Yasumoto R, Kawano M, Tsujino T, et al. Seminl plasma cytokines in nonbacterial prostatitis:changes following cytokines in nonbacterial prostatitis:changes following 1731 sparftoxacin treatment [J]. Hinyokika Kiyo, 1995; 41(10):771
[86]Alexander RB, Ponniah S, Hasday J, et al. Elevated levels of proinflammatory cytoklnes In the semen of patients with chronic prostatitis. chronic pelvic pain syndrome [J]. Urology,1998; 52(5):744
[87]Harris MT, Feldberg RS, Lan KM, et al. Expression of proinflammatory genes during estrogen—induced inflare mation of the rat prostate[J]. Prostate, 2000,44(1):1988.Lang MD, Nickel JC, Olson M E, et al. Rat model of experimentally induced abacterial Protatit is[J]. Prostate,2000; 45(3):201
[89]扈风平,余平,舒明星,等.慢性前列腺炎Ⅱ-8和NO水平测定初探[J].湖南医科大学学报,1998；23(6)：566
[90]范治璐,马悦,张萍,等.慢性非细菌性前列腺炎免疫学病因的探讨[J].中华泌尿外科杂志,2000；21(7)：446
[91]Shoskes DA, Albakri Q, Thomas K. Cytokine polymorphisms in men with chronic prostatitis/chronic pelvic pain syndrome: association with diagnosis and treatment response[J]. J Urol,2002; 168(1):331
[92]Nadler RB, Koch AE, Calhoun EA, et al. IL-113 And TNFa in prostatic secretions are indicators in the evaluation of men with chronic prostaMeardtitis[J]. J Urol,2000; 164(2):214
[93]Yasumoto R, Kawano M, Tsujino T, et al. Seminl plasma cytokines in nonbacterial prostatitis:changes following cytokines in nonbacterial prostatitis:changes following sparftoxacin treatment[J]. Hinyokika Kiyo, 1995; 41(10):771
[94]Robinette CI. Sex-hommone-induced inflammation and fibromuscular proliferation in the rat lateral prostate[J]. Prostate,1998; 12(3):271
[95]Harris MT, Feldberg RS, Lau KM, et al. Expression of proinflammatory genes during estrogen-induced inflammation of rat prostate[J]. Prostate,2000; 44(1):14
[96]Orhan I, Onur R, Ilhan N. Seminal plasma cytokine levels in the diagnosis of chronic pelvic pain syndrome[J]. Int J Urol,2001; 8(9):495
[97]蒋立诚,裘宇容,张志波.前列腺液B因子、C反应蛋白、转铁蛋白和免疫球蛋白与慢性非细菌性前列腺炎的关系[J].中华男性学杂志,2001；3：178
[98]Ponniah S, Arah 1, Alexander RB. PSA is a candidate selfantigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome [J]. Prostate,2000; 44(1): 49
[99]Shahed AR, Shoskes DA. Correlation of~3-endorphin and proslaglandin E2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response [J]. J Urol,2001; 66:1738
[100]Miller LJ, Fischer KA, Goralnick SJ. Nerve growth factor and chronic prostatitis/chronic pelvic pain syndrome[J]. Urology,2002; 59(4):603
[101]Nickel JC. Prostatitis:myths and realities[J]. Urology,1998; 51(3): 362
[102]Nadler R, Koch A, Cambell P, et al. Interdeukinl-8 level in men with chronic prostatitis pelvic pain syndrome[J]. J Urol,1998; 271A
[103]Razumov SV, Medvedev AA, Chirun NV. Role of cytokines in the diagnosis of chronic prostatitis[J]. Urologia,2003; (6):25
[104]Kastner C, Jakse G. Measurement of immunoglobulins in seminal fluid with modified nephelometry an alternative diagnostic tool for chronic prostatitis[J]. Prostate Cancer Prostatic Dis,2003; 6(1):86
[105]Nickel JCC, Alexander R, Anderson R, et al.Prostatitis unplugged? Prostatic massage revisited[J]. Tech Urol,1999; 5:1
[106]Nickel JC, Downey J, Johnston B, et al. Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvie pain syndrome; a prospective mult icenter clinical trial [J]. J Urol,2001; 165(5): 1539
[107]朱喜山,负艳丽,王忍.慢性前列腺炎辅用免疫调解剂治疗的临床研究[J].中国综合临床,2002；8：745
[108]Cho YH, Lee sJ, Lee JV. Antibacterial effect of intra prostatic zinc injection in a rat model of chronic bacterial prostatitis[J]. Int J Antimicrob Agents,2002; 19(6):576
[109]Muraro G. Clinical study on the efficacy and safety of seaprose S combined with local prostatic hyperthermia in chronic nonbacterial prostatitis. Controlled study versus local prostatic hyperthermial[J]. Archivio Medicina Internal,1995; 47:73
[110]Wedren H. Effects of sodium pentosanpolysulphate On symptoms related to chronic non-bacterial prostatitis:a double-blind randomized study [J]. Scand J Urol Nephrol,1997; 21:81
[111]Bagavant H, Thompson C, Ohno K. Differential effect of neonatal thymectomy on systemic and organ specific autoimmune disease[J]. Int Immunol,2002; 14(12):1397
[112]Shoskes DA, Hakim L. Ghoniem G. Long-term results of multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome[J].J Urol,2003; 169(4):1406
[113]谭光忠,扬波.体外短波治疗慢性前列腺炎80例的临床观察[J].重庆医学,2003；11：1534
[114]Rivero V, Carnaud C, Riera CM. Prostatein or stervid binding protein (PSBP) induces experimental autoimmune prostatitis (EAP)in NOD mice[J]. Clin Immunol,2002; 105(2):176
[115]Batstone GR, Doble A, Gaston JS. Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS)[J]. Clin Exp Immunol,2002; 128(2):302
[116]John H, Maake C, Barghorn A. Immunological alterations in the aculate of chronic prostatitis patients:clues for autoimmunity[J]. Andrologia,2003; 35(5):294
[117]Diserio GP, Nowotny E. Experimental autoimmune protatitis:in vivo induction of the autoimmune response to lymphocytic soluble factors. Alterations at the endocrine metabolism level [J]. Am J Reprod Immunol, 1998; 39 (4):226
[118]Diserio GP, Nowotny E. Experimental autoimmune prostatitis: dihydrotestosterone influence over the immune response[J]. J Urol,2003; 170(6):2486
[119]徐从高,张茂宏,畅兴季,等.癌-肿瘤学原理和实践[M].济南：山东科学技术出版社.2000,5：49-70.
[120]陈灏珠.实用内科学[M].北京：人民卫生出版社.2002,11：94.
[121]何球藻,吴厚生,曹雪涛.细胞与分子免疫学[M].上海：上海科学技术文献出版社.1997,1：146.
[122]殷缨,张盈华,张利朝,等.恶性肿瘤患者T细胞亚群与红细胞免疫功能的变化及其相关性分析[J].实用癌症杂志,2001；16(2)：171-173.
[123]Soygur T,Beduk Y, Yaman 0, et al. Analysis of the PeriPheral blood lymPhocyte subsets in Patients with bladder carcinoma[J]. Urology,1999; 53(1): 88-91.
[124]Bentdal OH, Froland SS, Bosnes V, et al. Alteration of lymphocyte subsets in blood may Predict resectibility in carcinoma of cardia or oesoPhogus [J]. Cancer Letters,1996; 100:133-138.
[125]Liua Y, Poona RT. Hughesb J,et al. Chemokine receptors support infiltra-tion of lymphocyte subpopulations in human hepatocellular carcinoma[J].Clin Immunol,2005; 114:174,182.
[126]曹健,乔颖,陈大伟.胃肠道恶性肿瘤患者NK细胞和T细胞亚群的改变[J]中华肿瘤杂志,1997；19(2)：133-136.
[127]金从国,王熙才,伍治平,等.癌症患者外周血T细胞亚群水平及临床意义[J]肿瘤研究与临床,2003；15(1)：33-36.
[128]Cho Y, Miyamoto M, Kato K, et al. CD4+ and CD8+T cells cooPerate to imProve Prognosis of Patients with esoPhageal squamous cell carci noma[J]. Cancer Res, 2003; 63(7):1555-1559.
[129]鞠秀丽,孙念政,刘继玲,等.儿童急性淋巴细胞白血病患者T淋巴细胞免疫功能的研究.临床血液学杂志,2004；17(2)：84-86.
[130]Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymPhoma [J].Blood,2002; 99(12):4283-4297.
[131]齐士勇,王萌,徐勇.前列腺癌组织中树突状细胞的变化及以此为基础的免疫治疗[J].中华男科学杂志,2007；5(13)：453-456.
[132]郝素珍,王桂琴.实用医学免疫学[M].北京：高等教育出版社,2005；2：31-32.
[133]Ikeda H, Chamoto K,TSuji T,et al.The critical role of tyPe 1 innate and acquired immunity in tumor immunotheraPy[J]. Cancer Sci,2004; 95:697-703.
[134]Wu Y, Wan T, Zhou x,et al.HsP70-like Protein 1 fusion Protein enhances induction of carcinoembryonic antigen-sPecific CD8+ CTL resPon-se by dendritic cell vaccine[J]. Cancer Res,2005; 65:4947-4954.
[135]Gressner AM, Weiskirchen R, Breitkopf K, et al. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002; 7:d793. d807
[136]Nickel JC, Downey J, Young I, et al. Asymptomatic inflammation and/ or infection in benign prostatic hyperplasia. BJU Int,1999; 84(9):976-981
[137]Zatelli MC, Rossi R, Degli Uberti EC. Androgen influences transforming growth factor-beta 1 gene expression in human adrenocortical cells[J]. J Clin Endoerinol Metab,2000; 85(2):847-852.
[138]Shariat S F, Kim J H, Andrews B, et al. Preoperative plasma levels of transforming growth factor beta-1 strongly predict clinical outcome in patients with bladder carcinoma. Cancer,2001; 15,92(12):2985-2992.
[139]Cardillo M R, Petrangeli E, Perracchio L, et al. Transforming growth factor-beta expression in prostate neoplasia[J]. Anal Quant Cytol Histol, 2000; 22(1):1-10.
[140]Lane D, Gray EA, Mathur RS, ef af. Up-regulation of vascular endo—lhelial growth factor-C by nicotine in cewical cancer celllines. Am J Reprod Immunol; 2005; 53:153-158.
[141]Eder IE, Stenz JA, HobischA, etal. Expression of transforming growth factors beta.1. beta 2 and beta 3 In human bladder carcinomas. Br J Cancer,1997; 5:1753—1760.
[142]Tessitore L. Bollito E. Early induction of TGF. betal through a fastingre feeding regimen promotes liver carcinogenesis by a sub。Initiating dose of diethylnitrosamine. Cell Prol,2006; 39:105__116.
[143]Wolff JM, Fandel Borchers H, ef al. Transforming growth factor-betal serum concentration in patients with prostatic cancer and benign prostatic hyperplasia. Br J Urol,1998; 81:403-405.
[144]Yuejing Yang, Tao Sun. et al. TGF—β1 may be complimentary to PSA in Chinese prostate cancer. Chinese—German J Clin Oncol,2009; 8:168-171
[145]Shariat SF, Shalev M, Menesses. Diaz A, et al. Preoperative plasma levels of transforming growth factor beta(1)(TGF-beta(1))strongly predict progression in patients undergoing radical prostatectomy J Clin Oncol.2001; 19:2856-2864.
[146]Lucia MS. Sporn MB. Robe,s AB. ef al. The role of transforming growth factor-betal,-beta2. and-beta3 in androgen—responsive growth of NRP-152 rat prostatic epithelial cells. J Cell Physiol.1998.175:184—192.
[147]Chipuk JE, Cornelius SC, Pultz NJ, et al. The androgen receptor re. presses transforming growth factor-beta signaling through interaction with Smad3. J Bigl Chem.2002.277:1240—1248.
[148]Diaw L, Roth M, Schwinn DA. et al. Characteristics of a human prostate stromal cell line related to its use in a stromal-epithelial coculture model for the study of cancer chemoprevention. In Vitro Cell Dev Bigl Anim.2005; 41:142—148.
[149]孙银铃,李培富,张保国.中医分型论治慢性前列腺炎浅谈.河南中医药学刊.2000；15(4)：62～63
[150]崔学教教授治疗慢性前列腺炎的特色[J].新中医.1999；31(5)： 2～13
[151]李新文.对慢性前列腺炎的中医治疗体会明.云南中医中药杂志,2002；23(2)：42
[152]彭贵云.非细菌性前列腺炎的中医辨证论治明.四川中医,2002；20(7)：40～41
[153]何永生,鲁冰丰.鲁贤昌治疗前列腺炎的经验[J].四川中医,2003；21(45～6
[154]厉将斌,陈仕成,李日庆.慢性前列腺炎的中医认识和治疗思路[J].云南中医学院学报,2003；26(2)：29～-31
[155]张国亭.慢性前列腺炎所致性功能障碍的中医辨证研究[J].河北中医,2001；23(5)：380～381
[156]张健斌.中医辨证施治慢性前列腺炎300例[J].宜春医专学报.2000；12(1)：40～41
[157]陈志强,谭志健,桂泽红.604例慢性前列腺炎患者的中医辨证分型调查分析[J].广州中医药大学学报,1997；14(3)：23～24
[158]张国亭.慢性前列腺炎的中医辨证及活血利湿补肾法的临床总结.中华实用中西医杂志,2004；4(17)：213～214
[159]瞿亚春.非细菌性前列腺炎中医证治研究[J].江苏中医,2001；22(9)9～12
[160]李恒山.浅谈慢性前列腺炎证治体会[J].新中医,1997,29(3)：
[161]孙银铃,李培富,张保国.中医分型论治慢性前列腺炎浅谈明.河南中医药学刊,2000；15(4)：62～63
[162]田质让,田映华.慢性列腺炎所致男性不育与性功能障碍的中医诊治.江西中 医药.2002；33(4)：34
[163]瞿亚春.非细菌性前列腺炎中医证治研究[J].江苏中医.2001；22(9)9～12
[164]乔艳荣,李晓慧.自拟前列通治疗慢性前列腺炎52例[J].陕西中医,2000,21(3)：114.
[165]周伟强,贾金铭.治疗慢性前列腺炎经验[J].实用中医药杂志,2003,19(6)：317.
[166]尹国良,刘旭生.黄春林治疗前列腺炎经验[J].中医杂志,2001,2(1)：19.
[167]厉将斌,陈仕成,李日庆.慢性前列腺炎的中医认识和治疗思路[J].云南中医学院学报,2003；26(2)：29～31
[168]鲍严钟,慢性前列腺炎分型辨治[J].江苏中医药,2006,27(5)；5
[169]陈玉聪,李云峰.八正散加减治疗前列腺炎68例[J].福建中医药,2002,22(6)：9.
[170]何世明.自拟精浊汤为主治疗慢性前列腺炎80例.中国医学文摘,2000；13卷,10期.
[171]徐福松.慢性前列腺炎治疗以补肾导浊为主法[J].江苏中医药,2006；27(5)：1
[172]孙中明.中西医结合治疗慢性前列腺炎50例[J].黑龙江中医药,1999；(5)：7.
[173]刘毅,王朋郎,蔡继红.中西医结合治疗慢性前列腺炎及相关疾病80例[J].湖南中医药导报,2000；6(2)：19—20.
[174]蔡洁武.活血利湿汤治疗慢性前列腺炎60例[J].实用中医药杂志,2001；17(10)：11
[175]徐新建,周智恒.清热化瘀法治疗慢性非细菌性前列腺炎80例[J].中国中西医结合外科杂志,2005：11(3)：243—244.
[176]谢坚,李慈春.加味血府逐瘀汤治疗慢性非细菌性前列腺炎80例临床观察[J].中国男科学杂志,2004；18(3)：36—37.
[177]李瑾.化瘀导浊汤治疗慢性前列腺炎70例[J].陕西中医,2004；25(8)；683
[178]梁杰,王聪一.自拟通淋汤治疗慢性前列腺炎48例[J].国医论坛,2001；16(6)：32—33.
[179]曾汉东.用益肾清浊通瘀法治疗慢性前列腺炎110例,黑龙江中医药,2000；5,10
[180]邹建安,葛峰,称久发,等.中西医结合治疗慢性细菌性前列腺炎[J].中国中西医结合外科杂志,2001；7(5),329-330
[181]龙家俊.张崎,陆新,等.前列健汤治疗慢性前列腺炎41例观察[J].实用中医药杂志,1999；15(6)：3-4.
[182]郑洪岭,中药内外合治慢性前列腺炎208例[J].天津中医,2007；35(12),27—28.
[183]攀学中.软坚散结化瘀降浊清热利湿法治疗前列腺增生症217例[J].新中医,1999；31(12)：26—27.
[184]蒋学洲,江京力,周智恒.中西结合治疗慢性前列腺炎80例[J].上海中医药杂志,2001；35(12),27—28.
[185]吴宁光.补肾化瘀通淋汤治疗慢性前列腺炎60例.山西中医,2004；20(2)；25.
[186]吴金虎,王刚,张晓燕,等.前愈汤对慢性前列腺炎局部免疫功能影响的实验研究湖北中医杂志,2006；28(3)：11-12.
[187]姚睿智,谢建兴,谢玉琼,等.清热利湿祛瘀中药经直肠给药对慢性前列腺炎患者局部免疫功能的影响,广州中医药大学学报,2009；26(1)：6-9
[188]王伊,王成李,孟建,等.热淋清颗粒对大鼠自身免疫性慢性前列腺炎治疗作用的实验研究.临床泌尿外科杂志,2009；24(3)228-232.
[189]Schaeffer AJ, Knauss JS, Landis JR, et al. Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis Cohort Study [J]. J Urol, 2002; 168(3):1048-1053.
[190]Mikolajczyk SD, Song Y, Wong JR, et al. Are multiple marker the future of prostate cancer diagnostics? Clinic Biochem 2004; 37:519-528
[191]Battikhi M N, Ismail H, Battikhi Q. Effects of bacterial prostatitis on prostate specific antigen levels total and free in patients with benigh prostatic hyperplasia and prostate cancer. nt Urol and Nephrol,2006; 38: 21-26.
[192]成凤韬,董英,慢性前列腺炎患者免疫功能与肾阳虚证的关系研究,河北中医2005；27(2)：2.
[193]李劲,陈闻纳,赖穗萍.尿道炎后慢性前列腺炎的实验室诊断.热带医学杂志,2005；5(3)：332-333.
[194]丁协刚,李世文,郑新民.慢性前列腺炎／慢性骨盆疼痛综合征患者前列腺液中IFN-γ、TGF-βl的检测.中华男科学杂志,2006；12(11)：982-893.
[2]Penson DF, Chan JM:Prostate Cancer. In Urologic Diseases in America. Edited by m n Litwin MS, Saigal CS. Washington, DC:US Government Printing Office,2007; [NIH Publication No.07-5512:71-122.]
[3]DeMarzo AM, Platz EA, Sutcliffe S, et al.:Inflammation in prostate carcinogenesis. Nat Rev Cancer,2007; 7:256-269.
[4]McNaughton-Collins M, Joyce GF, Wise M, Pontari MA:Prostatitis. In Urologic Diseases in America. Edited by Litwin MS, Saigal CS. Washington, DC: US Government Printing Office,,2007; [NIH Publication No.07-5512:9-42.]
[5]Roberts R0, Lieber MM, Bostwick DG, Jacobsen SJ:A review of clinical and pathological prostatitis syndromes. Urology,1997; 49:809-821.
[6]Roberts R0, Lieber MM, Rhodes T, et al.:Prevalence of a physician-assigned diagnosis of prostatitis:the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology,1998; 51:578-584.
[7]Dennis LK, Lynch CF, Torner JC:Epidemiologic association between prostatitis and prostate cancer. Urology,2002; 60:78-83.
[8]Sarma AV, McLaughlin JC, Wallner, et al.:Sexual behavior, sexually transmitted diseases, and prostatitis:the risk of prostate cancer in black men. J Urol,2006; 176:1108-1113.
[9]Coussens LM, Werb Z:Inflammation and cancer. Nature 2002,420:860-867.
[10]Basler JW, Piazza GA:Nonsteroidal anti-inflamatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol,2004; 171:S59-S63.
[11]DeMarzo AM, Marchi VL, Epstein JI, Nelson WG:Proliferative inflammatory atrophy of the prostate. Implications for prostate carcinogenesis. Am J Pathol,1999; 155:1985-1992.
[12]Shah R, Mucci NR, Amin A, et al.:Postatrophic hyperplasia of the prostate gland. Neoplastic precursor or innocent bystander? Am J Pathol,2001; 158: 1767-1773.
[13]Anton RC, Kattan MW, Chakraborty S, Wheeler TM:Postatrophic hyperplasia of the prostate:lack of association with prostate cancer. Am J Surg Pathol, 1999; 23:939-936.
[14]Gerstenbluth RE, Seftel AD, MacLennan GT, et al.:Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol,2002; 167:2267-2270.
[15]Bill is A, Magna LA:Inflammatory atrophy of the prostate. Arch Pathol Lab Med,2003; 127:840-844.
[16]MacLennan GT, Eisenberg R, Fleshman RL, et al.:The influence of chronic inflammation in prostatic carcinogenesis:a 5-year followup study. J Urol, 2006; 176:1012-1016.
[17]Konig JE, Senge T, Allhoff EP, Konig W:Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate,2004; 58:121-129.
[18]Zheng SL, Liu W, Wiklund F, et al.:A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. Prostate,2006; 66:1556-1564.
[19]Yoshimura R, Sano H, Masuda C, et al.:Expression of Cox-2 in prostate carcinoma. Cancer,2000; 89:589-596.
[20]National Institutes of Health Summary Statement. National Institute of Health/National Institute of Diabetes and Digestive and Kidney Diseases workshop on chronic prostatitis. Bethesda, MD:December 1995.
[21]Nickel JC, Nyberg LM, Hennenfent M:Research guidelines for chronic prostatitis:consensus report from the fi rst National Institutes of Health International Prostatitis Collaborative Network. Urology,1999; 54:229-233.
[22]True LD, Berger RE, Rothman I, et al.:Prostate histopathology and chronic prostatitis/chronic pelvic pain syndrome:a prospective biopsy study. J Urol, 1999; 162:2014-2018.
[23]Carver BS, Bozeman CB, William Bj, Venable DD:The prevalence of men with National Institutes of Health category IV prostatitis and association with serum prostate specific antigen. J Urol,2003; 169:589-591.
[24]Okada K, Kojima M, Naya Y, et al.:Correlation of histological inflammation in needle biopsy specimens with serum prostate-specific antigen levels in men with negative biopsy for prostate cancer. Urology,2000; 55:892-898.
[25]Stancik I, Luftenegger W, Klimpfinger M, et al.:Effect of NIH-IV prostatitis on free and free-to-total PSA. Eur Urol,2004; 46:760-764.
[26]Rowe WEJ, Laniado ME, Walker MM, Anup P:Incidental acute prostatic inflammation is associated with a lower percentage of free prostate-specific antigen than other benign conditions of the prostate:a prospective screening study. BJU Int,2006; 97:1039-1042.
[27]Bozeman CB, Carver BS, Eastham JA, Venable DD:Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol,2002; 167:1723-1726.
[28]Nadler RB, Collins MM, Propert KJ, et al.:Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/chronic pelvic pain syndrome. Urology,2006; 67:337-342.
[29]Potts JM:Prospective identification of National Institutes of Health category Ⅳ prostatitis in men with elevated prostate specific antigen. J Urol 2000; 164:1550-1553.
[30]MILLAN-RODRIGUEZ F, PALOU J, BUJONS-TUR A, et al. Acute bacterial prostatitis:two different sub-categories according to a previous manipulation of the lower urinary tract[J]. World J Urol,2006,24(1):45-50
[31]TERAI A, ISHITOYA S, MITSUMORI K, et al. Molecular epidemiological evidence for ascending urethral infection in acute bacterial prostatitis [J]. J Urol,2000; 164(6):1945-1947
[32]张杰秀,华立新,钱立新,等.急性前列腺炎综合治疗35例报告[J].中华泌尿外科杂志,2005；26(12)：855
[33]王景顺,田浩,朱建周.感染性前列腺炎五年来菌谱及耐药性分析[J].医学信息,2006；19(2)：299-301
[34]ANDREU A, STAPLETON AE, FENNELL C, et al. Urovirulence determinants in Escherichia coli strains causing prostatit is[J]. J Infect Dis,1997, 176(2):464-469
[35]曹伟,代洪,童明华,等.慢性前列腺炎细菌感染及耐药性监测[J].中华医院感染学杂志,2003；13(8)：791-793
[36]胡小朋,白文俊,朱积川,等.慢性前列腺炎细菌及免疫学研究[J].中华泌尿外科杂志,2002；23(1)：29-31
[37]程力明,马文辉,赖秋亮,等.531例慢性前列腺炎病原体分析[J].中华男科学,2004；10(1)：64-65 185
[38]RIEGEL P, RUIMY R, DE BRIEL D, et al. Corynebacterium seminale sp. nov. a new species associated with genital infections in male patients[J]. J Clin Microbiol,1995; 33(9):2244-2249
[39]ROWE E, SMITH C, LAVERICK L, et al. A prospective, randomized, placebo controlled, double-blind study of pelvic electromagnetic therapy for the treatment of chronic pelvic pain syndrome with 1 year of followup[J]. J Urol, 2005; 173(6):2044-2047
[40]PONTARI MA, MCNAUGHTON-COLLINS M, O'LEARY MP, et al. The CPCRN Study Group. A case-control study of risk factors in men with chronic pelvic pain syndrome[J]. BJU Int,2005; 96(4):559-565
[41]孟安启,郑少斌,陈彤,等.慢性前列腺炎发病的多因素分析[J].第一军医大学学报,2002；22(9)：846-848
[42]SHORTLIFFE LM, SELLERS RG, SCHACHTER J. The characterization of nonbacterial prostatitis:search for an etiology[J]. J Urol,1992; 148(5):1461-1466
[43]PAVONE C, CALDARERA E, LIBERTI P, et al. Correlation between chronic prostatitis syndrome and pelvic venous disease:a survey of 2,554 urologic outpatients [J]. Eur Urol,2000; 37(4):400-403
[44]FORREST JB, SCHMIDT S. Interstitial cystitis, chronic nonbacterial prostatitis and chronic pelvic pain syndrome in men:a common and frequently identical clinical entity[J]. J Urol,2004; 172(6 Pt 2):2561-2562
[45]RILEY DE, BERGER RE, MINER DC, et al. Diverse and related 16S rRNA-encoding DNA sequences in prostate tissues of men with chronic prostatitis[J]. J Clin Microbiol,1998; 36(6):1646-1652
[46]ORHAN I, ONUR R, ILHAN N, et al. Seminal plasma cytokine levels in the diagnosis of chronic pelvic pain syndrome[J]. Int J Urol,2001; 8(9):495 499
[47]SZOKE I, TOROK L, D'OSA E, et al:The possible role of anaerobic bacteria in chronic prostatitis[J]. Int J Androl,1998,21 (3):163-168
[48]吕厚东,曹卉,李荣华,等.细菌L型与前列腺炎[J].男性学杂志,1994；8(3)：160 161.
[49]洪伟平,林观平,柯水源,等.性传播性尿道炎后慢性前列腺炎(附86例报告)[J].中华泌尿外科杂志,2002；23(5)：299-300
[50]OHKAWA M, YAMAGUCHI K, TOKUNAGA S, et al:Ureaplasma urealyticum in the urogenital tract of patients with chronic prostatitis or related symptomatology[J]. Br J Urol,1993; 186 72:918-921
[51]邓春华,梁宏,梅骅,等.前列腺内尿液反流在慢性前列腺炎发病中的作用[J].中华泌尿外科杂志,1998；19(6)：288-289
[52]PERSSON BE, RONQUISt G. Evidence for a mechanistic association between nonbacterial prostatitis and levels of urate and creatinine in expressed prostatic secretion[J]. J Urol,1996;155:958-960
[53]GHOBISH AA. Quantitative and qualitative assessment of flowmetrograms in patients with prostatodynia[J]. Eur Urol,2000; 38:576-583
[54]宋波,刘志平,金锡御,等.功能性膀胱下尿路梗阻与慢性前列腺炎[J].中华泌尿外科杂志,1995；16(2)：78
[55]MEHIK A, HELLSTROM P, LUKKARINEN 0, et al. Increased intraprostatic pressure in patients with chronic prostatitis[J]. Urol Res,1999; 27(4):277-279
[56]陈群,王翠华,严志强,等.慢性前列腺炎病人情绪因素与森田疗法[J],中华男科学,2003；9(9)：676—678
[57]陈修德,郑宝钟,金讯波,等.慢性前列腺炎的心理障碍及治疗[J],中华男科学,2004；10(2)：112-114
[58]TRIPP DA, CURTIS NICKEL J, LANDIS JR, et al. CPCRN Study Group. Predictors of quality of life and pain in chronic prostatitis/chronic pelvic pain syndrome: findings from the National Institutes of Health Chronic Prostatitis Cohort Study[J]. BJU Int,2004; 94(9):1279-1282
[59]HETRICK DC, CIOL MA, ROTHMAN I, et al. Musculoskeletal dysfunction in men with chronic pelvic pain syndrome type III:a case-control study[J]. J Urol,2003; 170(3):828-831
[60]周占松,宋波,卢根生,等.前列腺炎性疼痛与脊髓星形胶质细胞活化关系的研究[J].第三军医大学学报,2005；27(18)：1853-1854。
[61]陈勇,宋波,熊恩庆,等.前列腺与会阴盆底联系的电刺激研究[J].中华泌尿外科杂志,2004；25(2)：124-126
[62]SHAHED AR, SHOSKES DA. Correlation of beta-endorphin and prostaglandin E2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response[J]. J Urol,2001; 166 (5):1738-1741
[63]罗建辉,熊恩庆,宋波,等.非细菌性炎性刺激大鼠前列腺对膀胱功能影响的实验研究[J].第三军医大学学报,2005；27(21)：2145 2147 187
[64]周占松,宋波,卢根生,等.慢性前列腺炎牵涉痛神经机制及其膀胱、盆底肌的关系[J].解放军医学杂志,2005；30(12)：1055-1057
[65]周占松,宋波,卢根生,等.前列腺、膀胱及盆底肌伤害感受神经元在脊髓中的分布及其关系的研究[J].第三军医大学学报,2006；28(2)：157-159
[66]ALEXANDER RB, BRADY F, PONNIAH S. Autoimmune prostatitis:evidence of T cell reactivity with normal prostatic proteins [J]. Urology,1997; 50(6):893-899
[67]BATSTONE GR, DOBLE A, GASTON JS. Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS) [J]. Clin Exp Immunol,2002; 128(2):302-307
[68]JOHN H, BARGHORN A, FUNKE G, et al. Noninflammatory chronic pelvic pain syndrome:immunological study in blood, ejaculate and prostate tissue [J]. Eur Urol,2001; 39 (1):72-78
[69]DOBLE A, WALKER MM, HARRIS JR, et al. Intraprostatic antibody deposition in chronic abacterial prostatitis[J]. Br J Urol,1990,65(6):598-605
[70]范治璐,马悦,张萍,等.慢性非细菌性前列腺炎免疫学病因的探讨[J].中华泌尿外科杂志,2000；21(7)：446
[71]ALEXANDER RB, PONNIAH S, HASDAY J, et al. Elevated levels of proinflammatory cytokines in the semen of patients withchronic prostatitis/chronic pelvic pain syndrome[J]. Urology,52 (5):744-749
[72]NADLER RB, KOCH AE, CAMPBELL PL, et al. IL-1 beta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic pros tatitis [J]. J Urol,2000; 164(1):214-218
[73]SHAHED AR, SHOSKES DA. Oxidative stress in prostatic fluid of patients with chronic pelvic pain syndrome:correlation with gram positive bacterial growth and treatment response [J]. J Androl,2000; 21 (5):669-675
[74]PASQUALOTTO FF, SHARMA RK, POTTS JM, et al. Seminal oxidative stress in patients with chronic prostatitis[J]. Urology,2000; 55(6):881-5
[75]ORSILLES MA, DEPIANTE-DEPAOLI M. Oxidative stress-related parameters in prostate of rats with experimental autoimmune prostatitis[J]. Prostate,1998; 34(4):270-274
[76]VICARI E. Effectiveness and limits of antimicrobial treatment on seminal leukocyte concentration and related reactive oxygen species production in patients with male accessory gland infection[J]. Hum Reprod,2000; 15(12):2536-2544 188
[77]ZHOU JF, XIAO WQ, ZHENG YC, et al. Increased oxidative stress and oxidative damage associated with chronic bacterial prostatitis[J]. Asian J Androl,2006; 8(3):317-323
[78]NICKEL JC, ALEXANDER RB, SCHAEFFER AJ, et al. Chronic Prostatitis Collaborative Research Network Study Group. Leukocytes and bacteria in men with chronic prostatitis/chronic pelvic pain syndrome compared to asymptomatic controls[J]. J Urol,2003; 170(3):818-822
[79]Alexander RB, Ponniah S, Hasday J, et al. Elevated levels of proinflammatory cytoklnes In the semen of patients with chronic prostatitis. chronic pelvic pain syndrome[J]. Urology,1998; 52(5):744
[80]Rivero V, Carnaud C, Riera CM. Prostatein or stervid binding protein (PSBP) induces experimental autoimmune prostatitis(EAP) in NOD mice[J]. Clin Immunol,2002; 105(2):176
[81]Batstone GR, Doble A, Gaston JS. Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS)[J]. Clin Exp Immunol,2002; 128(2):302
[82]John H, Maake C, Barghorn A. Immunological alterations in the~aculate of chronic prostatitis patients:clues for autoimmunity[J]. Andrologia,2003; 35(5):294
[83]Diserio GP, Nowotny E. Experimental autoimmune protatitis:in vivo induction of the autoimmune response to lymphocytic soluble factors. Alterations at the endocrine metabolism level[J]. Am J Reprod Immunol,1998; 39(4):226
[84]Diserio GP, Nowotny E. Experimental autoimmune prostatitis: dihydrotestosterone influence over the immune response[J]. J Urol,2003; 170(6 Pt 1):2486
[85]Yasumoto R, Kawano M, Tsujino T, et al. Seminl plasma cytokines in nonbacterial prostatitis:changes following cytokines in nonbacterial prostatitis:changes following 1731 sparftoxacin treatment [J]. Hinyokika Kiyo, 1995; 41(10):771
[86]Alexander RB, Ponniah S, Hasday J, et al. Elevated levels of proinflammatory cytoklnes In the semen of patients with chronic prostatitis. chronic pelvic pain syndrome [J]. Urology,1998; 52(5):744
[87]Harris MT, Feldberg RS, Lan KM, et al. Expression of proinflammatory genes during estrogen—induced inflare mation of the rat prostate[J]. Prostate, 2000,44(1):1988.Lang MD, Nickel JC, Olson M E, et al. Rat model of experimentally induced abacterial Protatit is[J]. Prostate,2000; 45(3):201
[89]扈风平,余平,舒明星,等.慢性前列腺炎Ⅱ-8和NO水平测定初探[J].湖南医科大学学报,1998；23(6)：566
[90]范治璐,马悦,张萍,等.慢性非细菌性前列腺炎免疫学病因的探讨[J].中华泌尿外科杂志,2000；21(7)：446
[91]Shoskes DA, Albakri Q, Thomas K. Cytokine polymorphisms in men with chronic prostatitis/chronic pelvic pain syndrome: association with diagnosis and treatment response[J]. J Urol,2002; 168(1):331
[92]Nadler RB, Koch AE, Calhoun EA, et al. IL-113 And TNFa in prostatic secretions are indicators in the evaluation of men with chronic prostaMeardtitis[J]. J Urol,2000; 164(2):214
[93]Yasumoto R, Kawano M, Tsujino T, et al. Seminl plasma cytokines in nonbacterial prostatitis:changes following cytokines in nonbacterial prostatitis:changes following sparftoxacin treatment[J]. Hinyokika Kiyo, 1995; 41(10):771
[94]Robinette CI. Sex-hommone-induced inflammation and fibromuscular proliferation in the rat lateral prostate[J]. Prostate,1998; 12(3):271
[95]Harris MT, Feldberg RS, Lau KM, et al. Expression of proinflammatory genes during estrogen-induced inflammation of rat prostate[J]. Prostate,2000; 44(1):14
[96]Orhan I, Onur R, Ilhan N. Seminal plasma cytokine levels in the diagnosis of chronic pelvic pain syndrome[J]. Int J Urol,2001; 8(9):495
[97]蒋立诚,裘宇容,张志波.前列腺液B因子、C反应蛋白、转铁蛋白和免疫球蛋白与慢性非细菌性前列腺炎的关系[J].中华男性学杂志,2001；3：178
[98]Ponniah S, Arah 1, Alexander RB. PSA is a candidate selfantigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome [J]. Prostate,2000; 44(1): 49
[99]Shahed AR, Shoskes DA. Correlation of~3-endorphin and proslaglandin E2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response [J]. J Urol,2001; 66:1738
[100]Miller LJ, Fischer KA, Goralnick SJ. Nerve growth factor and chronic prostatitis/chronic pelvic pain syndrome[J]. Urology,2002; 59(4):603
[101]Nickel JC. Prostatitis:myths and realities[J]. Urology,1998; 51(3): 362
[102]Nadler R, Koch A, Cambell P, et al. Interdeukinl-8 level in men with chronic prostatitis pelvic pain syndrome[J]. J Urol,1998; 271A
[103]Razumov SV, Medvedev AA, Chirun NV. Role of cytokines in the diagnosis of chronic prostatitis[J]. Urologia,2003; (6):25
[104]Kastner C, Jakse G. Measurement of immunoglobulins in seminal fluid with modified nephelometry an alternative diagnostic tool for chronic prostatitis[J]. Prostate Cancer Prostatic Dis,2003; 6(1):86
[105]Nickel JCC, Alexander R, Anderson R, et al.Prostatitis unplugged? Prostatic massage revisited[J]. Tech Urol,1999; 5:1
[106]Nickel JC, Downey J, Johnston B, et al. Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvie pain syndrome; a prospective mult icenter clinical trial [J]. J Urol,2001; 165(5): 1539
[107]朱喜山,负艳丽,王忍.慢性前列腺炎辅用免疫调解剂治疗的临床研究[J].中国综合临床,2002；8：745
[108]Cho YH, Lee sJ, Lee JV. Antibacterial effect of intra prostatic zinc injection in a rat model of chronic bacterial prostatitis[J]. Int J Antimicrob Agents,2002; 19(6):576
[109]Muraro G. Clinical study on the efficacy and safety of seaprose S combined with local prostatic hyperthermia in chronic nonbacterial prostatitis. Controlled study versus local prostatic hyperthermial[J]. Archivio Medicina Internal,1995; 47:73
[110]Wedren H. Effects of sodium pentosanpolysulphate On symptoms related to chronic non-bacterial prostatitis:a double-blind randomized study [J]. Scand J Urol Nephrol,1997; 21:81
[111]Bagavant H, Thompson C, Ohno K. Differential effect of neonatal thymectomy on systemic and organ specific autoimmune disease[J]. Int Immunol,2002; 14(12):1397
[112]Shoskes DA, Hakim L. Ghoniem G. Long-term results of multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome[J].J Urol,2003; 169(4):1406
[113]谭光忠,扬波.体外短波治疗慢性前列腺炎80例的临床观察[J].重庆医学,2003；11：1534
[114]Rivero V, Carnaud C, Riera CM. Prostatein or stervid binding protein (PSBP) induces experimental autoimmune prostatitis (EAP)in NOD mice[J]. Clin Immunol,2002; 105(2):176
[115]Batstone GR, Doble A, Gaston JS. Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS)[J]. Clin Exp Immunol,2002; 128(2):302
[116]John H, Maake C, Barghorn A. Immunological alterations in the aculate of chronic prostatitis patients:clues for autoimmunity[J]. Andrologia,2003; 35(5):294
[117]Diserio GP, Nowotny E. Experimental autoimmune protatitis:in vivo induction of the autoimmune response to lymphocytic soluble factors. Alterations at the endocrine metabolism level [J]. Am J Reprod Immunol, 1998; 39 (4):226
[118]Diserio GP, Nowotny E. Experimental autoimmune prostatitis: dihydrotestosterone influence over the immune response[J]. J Urol,2003; 170(6):2486
[119]徐从高,张茂宏,畅兴季,等.癌-肿瘤学原理和实践[M].济南：山东科学技术出版社.2000,5：49-70.
[120]陈灏珠.实用内科学[M].北京：人民卫生出版社.2002,11：94.
[121]何球藻,吴厚生,曹雪涛.细胞与分子免疫学[M].上海：上海科学技术文献出版社.1997,1：146.
[122]殷缨,张盈华,张利朝,等.恶性肿瘤患者T细胞亚群与红细胞免疫功能的变化及其相关性分析[J].实用癌症杂志,2001；16(2)：171-173.
[123]Soygur T,Beduk Y, Yaman 0, et al. Analysis of the PeriPheral blood lymPhocyte subsets in Patients with bladder carcinoma[J]. Urology,1999; 53(1): 88-91.
[124]Bentdal OH, Froland SS, Bosnes V, et al. Alteration of lymphocyte subsets in blood may Predict resectibility in carcinoma of cardia or oesoPhogus [J]. Cancer Letters,1996; 100:133-138.
[125]Liua Y, Poona RT. Hughesb J,et al. Chemokine receptors support infiltra-tion of lymphocyte subpopulations in human hepatocellular carcinoma[J].Clin Immunol,2005; 114:174,182.
[126]曹健,乔颖,陈大伟.胃肠道恶性肿瘤患者NK细胞和T细胞亚群的改变[J]中华肿瘤杂志,1997；19(2)：133-136.
[127]金从国,王熙才,伍治平,等.癌症患者外周血T细胞亚群水平及临床意义[J]肿瘤研究与临床,2003；15(1)：33-36.
[128]Cho Y, Miyamoto M, Kato K, et al. CD4+ and CD8+T cells cooPerate to imProve Prognosis of Patients with esoPhageal squamous cell carci noma[J]. Cancer Res, 2003; 63(7):1555-1559.
[129]鞠秀丽,孙念政,刘继玲,等.儿童急性淋巴细胞白血病患者T淋巴细胞免疫功能的研究.临床血液学杂志,2004；17(2)：84-86.
[130]Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymPhoma [J].Blood,2002; 99(12):4283-4297.
[131]齐士勇,王萌,徐勇.前列腺癌组织中树突状细胞的变化及以此为基础的免疫治疗[J].中华男科学杂志,2007；5(13)：453-456.
[132]郝素珍,王桂琴.实用医学免疫学[M].北京：高等教育出版社,2005；2：31-32.
[133]Ikeda H, Chamoto K,TSuji T,et al.The critical role of tyPe 1 innate and acquired immunity in tumor immunotheraPy[J]. Cancer Sci,2004; 95:697-703.
[134]Wu Y, Wan T, Zhou x,et al.HsP70-like Protein 1 fusion Protein enhances induction of carcinoembryonic antigen-sPecific CD8+ CTL resPon-se by dendritic cell vaccine[J]. Cancer Res,2005; 65:4947-4954.
[135]Gressner AM, Weiskirchen R, Breitkopf K, et al. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002; 7:d793. d807
[136]Nickel JC, Downey J, Young I, et al. Asymptomatic inflammation and/ or infection in benign prostatic hyperplasia. BJU Int,1999; 84(9):976-981
[137]Zatelli MC, Rossi R, Degli Uberti EC. Androgen influences transforming growth factor-beta 1 gene expression in human adrenocortical cells[J]. J Clin Endoerinol Metab,2000; 85(2):847-852.
[138]Shariat S F, Kim J H, Andrews B, et al. Preoperative plasma levels of transforming growth factor beta-1 strongly predict clinical outcome in patients with bladder carcinoma. Cancer,2001; 15,92(12):2985-2992.
[139]Cardillo M R, Petrangeli E, Perracchio L, et al. Transforming growth factor-beta expression in prostate neoplasia[J]. Anal Quant Cytol Histol, 2000; 22(1):1-10.
[140]Lane D, Gray EA, Mathur RS, ef af. Up-regulation of vascular endo—lhelial growth factor-C by nicotine in cewical cancer celllines. Am J Reprod Immunol; 2005; 53:153-158.
[141]Eder IE, Stenz JA, HobischA, etal. Expression of transforming growth factors beta.1. beta 2 and beta 3 In human bladder carcinomas. Br J Cancer,1997; 5:1753—1760.
[142]Tessitore L. Bollito E. Early induction of TGF. betal through a fastingre feeding regimen promotes liver carcinogenesis by a sub。Initiating dose of diethylnitrosamine. Cell Prol,2006; 39:105__116.
[143]Wolff JM, Fandel Borchers H, ef al. Transforming growth factor-betal serum concentration in patients with prostatic cancer and benign prostatic hyperplasia. Br J Urol,1998; 81:403-405.
[144]Yuejing Yang, Tao Sun. et al. TGF—β1 may be complimentary to PSA in Chinese prostate cancer. Chinese—German J Clin Oncol,2009; 8:168-171
[145]Shariat SF, Shalev M, Menesses. Diaz A, et al. Preoperative plasma levels of transforming growth factor beta(1)(TGF-beta(1))strongly predict progression in patients undergoing radical prostatectomy J Clin Oncol.2001; 19:2856-2864.
[146]Lucia MS. Sporn MB. Robe,s AB. ef al. The role of transforming growth factor-betal,-beta2. and-beta3 in androgen—responsive growth of NRP-152 rat prostatic epithelial cells. J Cell Physiol.1998.175:184—192.
[147]Chipuk JE, Cornelius SC, Pultz NJ, et al. The androgen receptor re. presses transforming growth factor-beta signaling through interaction with Smad3. J Bigl Chem.2002.277:1240—1248.
[148]Diaw L, Roth M, Schwinn DA. et al. Characteristics of a human prostate stromal cell line related to its use in a stromal-epithelial coculture model for the study of cancer chemoprevention. In Vitro Cell Dev Bigl Anim.2005; 41:142—148.
[149]孙银铃,李培富,张保国.中医分型论治慢性前列腺炎浅谈.河南中医药学刊.2000；15(4)：62～63
[150]崔学教教授治疗慢性前列腺炎的特色[J].新中医.1999；31(5)： 2～13
[151]李新文.对慢性前列腺炎的中医治疗体会明.云南中医中药杂志,2002；23(2)：42
[152]彭贵云.非细菌性前列腺炎的中医辨证论治明.四川中医,2002；20(7)：40～41
[153]何永生,鲁冰丰.鲁贤昌治疗前列腺炎的经验[J].四川中医,2003；21(45～6
[154]厉将斌,陈仕成,李日庆.慢性前列腺炎的中医认识和治疗思路[J].云南中医学院学报,2003；26(2)：29～-31
[155]张国亭.慢性前列腺炎所致性功能障碍的中医辨证研究[J].河北中医,2001；23(5)：380～381
[156]张健斌.中医辨证施治慢性前列腺炎300例[J].宜春医专学报.2000；12(1)：40～41
[157]陈志强,谭志健,桂泽红.604例慢性前列腺炎患者的中医辨证分型调查分析[J].广州中医药大学学报,1997；14(3)：23～24
[158]张国亭.慢性前列腺炎的中医辨证及活血利湿补肾法的临床总结.中华实用中西医杂志,2004；4(17)：213～214
[159]瞿亚春.非细菌性前列腺炎中医证治研究[J].江苏中医,2001；22(9)9～12
[160]李恒山.浅谈慢性前列腺炎证治体会[J].新中医,1997,29(3)：
[161]孙银铃,李培富,张保国.中医分型论治慢性前列腺炎浅谈明.河南中医药学刊,2000；15(4)：62～63
[162]田质让,田映华.慢性列腺炎所致男性不育与性功能障碍的中医诊治.江西中 医药.2002；33(4)：34
[163]瞿亚春.非细菌性前列腺炎中医证治研究[J].江苏中医.2001；22(9)9～12
[164]乔艳荣,李晓慧.自拟前列通治疗慢性前列腺炎52例[J].陕西中医,2000,21(3)：114.
[165]周伟强,贾金铭.治疗慢性前列腺炎经验[J].实用中医药杂志,2003,19(6)：317.
[166]尹国良,刘旭生.黄春林治疗前列腺炎经验[J].中医杂志,2001,2(1)：19.
[167]厉将斌,陈仕成,李日庆.慢性前列腺炎的中医认识和治疗思路[J].云南中医学院学报,2003；26(2)：29～31
[168]鲍严钟,慢性前列腺炎分型辨治[J].江苏中医药,2006,27(5)；5
[169]陈玉聪,李云峰.八正散加减治疗前列腺炎68例[J].福建中医药,2002,22(6)：9.
[170]何世明.自拟精浊汤为主治疗慢性前列腺炎80例.中国医学文摘,2000；13卷,10期.
[171]徐福松.慢性前列腺炎治疗以补肾导浊为主法[J].江苏中医药,2006；27(5)：1
[172]孙中明.中西医结合治疗慢性前列腺炎50例[J].黑龙江中医药,1999；(5)：7.
[173]刘毅,王朋郎,蔡继红.中西医结合治疗慢性前列腺炎及相关疾病80例[J].湖南中医药导报,2000；6(2)：19—20.
[174]蔡洁武.活血利湿汤治疗慢性前列腺炎60例[J].实用中医药杂志,2001；17(10)：11
[175]徐新建,周智恒.清热化瘀法治疗慢性非细菌性前列腺炎80例[J].中国中西医结合外科杂志,2005：11(3)：243—244.
[176]谢坚,李慈春.加味血府逐瘀汤治疗慢性非细菌性前列腺炎80例临床观察[J].中国男科学杂志,2004；18(3)：36—37.
[177]李瑾.化瘀导浊汤治疗慢性前列腺炎70例[J].陕西中医,2004；25(8)；683
[178]梁杰,王聪一.自拟通淋汤治疗慢性前列腺炎48例[J].国医论坛,2001；16(6)：32—33.
[179]曾汉东.用益肾清浊通瘀法治疗慢性前列腺炎110例,黑龙江中医药,2000；5,10
[180]邹建安,葛峰,称久发,等.中西医结合治疗慢性细菌性前列腺炎[J].中国中西医结合外科杂志,2001；7(5),329-330
[181]龙家俊.张崎,陆新,等.前列健汤治疗慢性前列腺炎41例观察[J].实用中医药杂志,1999；15(6)：3-4.
[182]郑洪岭,中药内外合治慢性前列腺炎208例[J].天津中医,2007；35(12),27—28.
[183]攀学中.软坚散结化瘀降浊清热利湿法治疗前列腺增生症217例[J].新中医,1999；31(12)：26—27.
[184]蒋学洲,江京力,周智恒.中西结合治疗慢性前列腺炎80例[J].上海中医药杂志,2001；35(12),27—28.
[185]吴宁光.补肾化瘀通淋汤治疗慢性前列腺炎60例.山西中医,2004；20(2)；25.
[186]吴金虎,王刚,张晓燕,等.前愈汤对慢性前列腺炎局部免疫功能影响的实验研究湖北中医杂志,2006；28(3)：11-12.
[187]姚睿智,谢建兴,谢玉琼,等.清热利湿祛瘀中药经直肠给药对慢性前列腺炎患者局部免疫功能的影响,广州中医药大学学报,2009；26(1)：6-9
[188]王伊,王成李,孟建,等.热淋清颗粒对大鼠自身免疫性慢性前列腺炎治疗作用的实验研究.临床泌尿外科杂志,2009；24(3)228-232.
[189]Schaeffer AJ, Knauss JS, Landis JR, et al. Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis Cohort Study [J]. J Urol, 2002; 168(3):1048-1053.
[190]Mikolajczyk SD, Song Y, Wong JR, et al. Are multiple marker the future of prostate cancer diagnostics? Clinic Biochem 2004; 37:519-528
[191]Battikhi M N, Ismail H, Battikhi Q. Effects of bacterial prostatitis on prostate specific antigen levels total and free in patients with benigh prostatic hyperplasia and prostate cancer. nt Urol and Nephrol,2006; 38: 21-26.
[192]成凤韬,董英,慢性前列腺炎患者免疫功能与肾阳虚证的关系研究,河北中医2005；27(2)：2.
[193]李劲,陈闻纳,赖穗萍.尿道炎后慢性前列腺炎的实验室诊断.热带医学杂志,2005；5(3)：332-333.
[194]丁协刚,李世文,郑新民.慢性前列腺炎／慢性骨盆疼痛综合征患者前列腺液中IFN-γ、TGF-βl的检测.中华男科学杂志,2006；12(11)：982-893.